Table 4.
Age: summary of studies reporting analysis of age as a prognostic factor
| Author (reference) | Quality | Year | Patients | Age | Age group | Patients | Outcome studied | Result | Comment | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | Mean | Range | |||||||||
| Sandler [64] | A | 1992 | 21 | 21 | NR | 0.75–70 | Median 31 years | 9 | Recurrence | Yes (↓) | Advanced age: shorter time to recurrence |
| Median 17 years | 12 | No (↑) | Younger age: no recurrence | ||||||||
| Huddart [24] | A | 1993 | 27 | 31 | NR | 6–69 | <16 | 5 | 5-year OS (%) | 80 | Not significant |
| 16–39 | 13 | 64 | |||||||||
| >39 | 9 | 38 | |||||||||
| Minehan [49] | A | 1995 | 79 | NR | NR | NR | >20 | 65 | Survival | Increased (↑) | p NR |
| Innocenzi [27] | B | 1997 | 65 | NR | 34.8 | 2–68 | 2–18 | 12 | 5-year OS (%) | 66 | Not significant |
| 19–50 | 41 | 61 | |||||||||
| >50 | 12 | 66 | |||||||||
| Przybylski [56] (p) | A | 1997 | 18 | 8.6 | 9.2 | 0.6–17.9 | NR | NR | Recurrence | No effect | |
| Jyothirmayi [30] | A | 1997 | 23 | NR | 31 | 3–57 | <18 | 5 | 5-year OS (%) | 60 | Not significant |
| 19–39 | 13 | 46 | |||||||||
| >40 | 5 | 80 | |||||||||
| Bouffet [5] (p) | A | 1998 | 73 | 7 | NR | 0.25–16 | <7 | 37 | 10-year OS (%) | 76 (↑) | p = 0.04 |
| >7 | 36 | 38 (↓) | |||||||||
| Rodrigues [60] | A | 2000 | 48 | 32 | NR | 2–76 | <18 | 13 | 5-year PFS/CSS (%) | 100/100 (↑) | p = 0.03 |
| >18 | 35 | 43/56 (↓) | |||||||||
| Kim [34] | A | 2001 | 28 | 36 | NR | 19–68 | 19–40 | 21 | Mean/median survival (months) | 91.9/– | p = 0.209, not significant |
| >40 | 7 | 56.2/11.0 | |||||||||
| Jallo [28] | A | 2001 | 17 | NR | 33 | 22–61 | NR | NR | Recurrence | No effect | |
| Santi [65] (m) | B | 2003 | 36 | 26 | 31.8 | 3–88 | <20 | 12 | Median survival (months) | 13 (↑) | p < 0.001 |
| 20–40 | 15 | 15 (↑) | |||||||||
| >40 | 9 | 3 (↓) | |||||||||
| Lee [41] | A | 2003 | 25 | 40 | 28 | 1–58 | “Older age” | NR | 5-year LC/PFS/OS | Adverse effect (↓) | “Older age” not defined, increased risk ratio |
| Robinson [59] | A | 2005 | 14 | 40.5 | 40.6 | 5.2–77.2 | NR | NR | 5-, 10-, 20-year OS, PFS | No effect | |
| Abdel-Wahab [2] | A | 2006 | 57 | 30 | NR | 1–69 | 10-year increase | NR | 15-year OS/PFS | No effect | |
| McGirt [46] (m) | A | 2008 | 35 | NR | 29 | 2–61 | NR | NR | Median survival | No effect | |
↑ positive influence on outcome measure, ↓ negative influence on outcome measure, p: series of pediatric patients, m: series of high-grade tumors